Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

TAK$21.41—
Drug Manufacturers - Specialty & GenericLarge CapGrowth Stock
Compare
Market cap$69.55BEnterprise value—Revenue (TTM)—Market positionTop 25%

Score

53
Neutral
Value
53
Quality
47
Growth
60

Takeda Pharmaceutical Company Limited analyst ratings

RatingAnalysts
Strong buy0
Buy3
Hold0
Sell0
Strong sell0
ConsensusBuy

3 analysts cover TAK.

Takeda Pharmaceutical Company Limited EPS and revenue estimates

Published annual figures for TAK on this page are 2026 EPS $71.80, 2027 EPS $68.00. Coverage under three analysts is omitted.

Fiscal yearEPS estimateRevenue estimate
2026$71.80$4.62T
2027$68.00$4.71T

Is Takeda Pharmaceutical Company Limited a buy or sell?

Of the 3 analysts covering Takeda Pharmaceutical Company Limited, 3 rate it a buy (0 strong buy and 3 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The TAK consensus label is Buy, beside 3 buy-side ratings and 0 sell-side ratings.

The TAK rating block is 3 published views with a Buy label. It does not tell you whether to buy or sell.

Reading the Takeda Pharmaceutical Company Limited forecast

The TAK rating mix is lopsided rather than split: 3 of 3 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.

the Takeda Pharmaceutical Company Limited has a falling EPS path, $71.80 for 2026 and $68.00 for 2027.

With 3 firms in the TAK target set, the average is a small sample.

Takeda Pharmaceutical Company Limited forecast questions

What is the TAK price target?

No published price target is on file for TAK.

Is Takeda Pharmaceutical Company Limited a buy or sell?

Of the 3 analysts covering Takeda Pharmaceutical Company Limited, 3 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, leaving TAK at 3 buy ratings, 0 holds, and 0 sells.

What is the EPS estimate for Takeda Pharmaceutical Company Limited?

Analyst EPS estimates for Takeda Pharmaceutical Company Limited: 2026 $71.80, 2027 $68.00.

What is the revenue estimate for Takeda Pharmaceutical Company Limited?

Analyst revenue estimates for Takeda Pharmaceutical Company Limited: 2026 $4.62T, 2027 $4.71T.

How many analysts cover TAK?

3 analysts cover TAK. Their consensus on TAK is Buy, across those 3.

TAK price $21.41 —

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener